The value of high dose tamoxifen in postmenopausal breast cancer patients progressing on standard doses: a pilot study.
作者信息
Watkins S M
机构信息
Department of Medical Oncology, Lister Hospital, Stevenage, Herts, UK.
出版信息
Br J Cancer. 1988 Mar;57(3):320-1. doi: 10.1038/bjc.1988.72.
Abstract
摘要
相似文献
1
The value of high dose tamoxifen in postmenopausal breast cancer patients progressing on standard doses: a pilot study.高剂量他莫昔芬对标准剂量治疗后病情进展的绝经后乳腺癌患者的价值：一项初步研究。
Br J Cancer. 1988 Mar;57(3):320-1. doi: 10.1038/bjc.1988.72.
2
Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer.他莫昔芬与氨鲁米特及他莫昔芬联合氨鲁米特治疗绝经后晚期乳腺癌的随机试验
Oncology. 1988;45(5):350-3. doi: 10.1159/000226639.
3
Ovarian volume in postmenopausal breast cancer patients treated with tamoxifen.接受他莫昔芬治疗的绝经后乳腺癌患者的卵巢体积
Gynecol Oncol. 1997 Jan;64(1):105-8. doi: 10.1006/gyno.1996.4512.
4
Tamoxifen in advanced breast cancer.他莫昔芬用于晚期乳腺癌
Cancer Treat Rev. 1978 Sep;5(3):131-41. doi: 10.1016/s0305-7372(78)80017-6.
5
Anti-oestrogen therapy for breast cancer--a report on 300 patients treated with tamoxifen.
Clin Oncol. 1978 Mar;4(1):11-7.
6
A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.两种剂量他莫昔芬（诺瓦得士）治疗绝经后晚期乳腺癌女性的比较：每日两次，每次10毫克与每日两次，每次20毫克。
Br J Cancer. 1984 Aug;50(2):199-205. doi: 10.1038/bjc.1984.163.
7
Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: an ultrasound, color flow Doppler, hysteroscopic and histological study.接受他莫昔芬治疗的绝经后乳腺癌患者的子宫内膜评估：一项超声、彩色多普勒血流、宫腔镜及组织学研究。
Ultrasound Obstet Gynecol. 1995 Dec;6(6):435-42. doi: 10.1046/j.1469-0705.1995.06060435.x.
8
Tamoxifen in the management of advanced breast carcinoma in Nigerian women.他莫昔芬用于尼日利亚女性晚期乳腺癌的治疗
West Afr J Med. 1990 Jan-Mar;9(1):44-9.
9
10
Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause aggravation of endometrial pathologies.
Gynecol Oncol. 1994 Oct;55(1):138-43. doi: 10.1006/gyno.1994.1263.
引用本文的文献
1
High-dose tamoxifen in high-hormone-receptor-expressing advanced breast cancer patients: a phase II pilot study.高剂量他莫昔芬用于高激素受体表达的晚期乳腺癌患者：一项II期试点研究。
Ther Adv Med Oncol. 2021 Feb 26;13:1758835921993436. doi: 10.1177/1758835921993436. eCollection 2021.
2
Genotype-guided tamoxifen therapy: time to pause for reflection?基因分型指导的他莫昔芬治疗：是时候停下来反思了？
Lancet Oncol. 2009 Aug;10(8):825-33. doi: 10.1016/S1470-2045(09)70030-0.
3
Tamoxifen metabolism: pharmacokinetic and in vitro study.他莫昔芬代谢：药代动力学及体外研究
Br J Cancer. 1989 Jul;60(1):30-5. doi: 10.1038/bjc.1989.214.
4
Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.他莫昔芬：对其药效学、药代动力学特性及治疗用途的重新评估
Drugs. 1989 Apr;37(4):451-90. doi: 10.2165/00003495-198937040-00004.
5
In vitro sensitivity test of breast cancer cells to hormonal agents in a radionucleotide-incorporation assay.通过放射性核苷酸掺入试验对乳腺癌细胞进行激素制剂的体外敏感性测试。
Jpn J Cancer Res. 1990 May;81(5):536-43. doi: 10.1111/j.1349-7006.1990.tb02603.x.
6
Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.晚期乳腺癌中使用的内分泌药物的临床药代动力学
Clin Pharmacokinet. 1992 May;22(5):327-58. doi: 10.2165/00003088-199222050-00002.
本文引用的文献
1
Tamoxifen-induced remission in breast cancer by escalating the dose to 40 mg daily after progression on 20 mg daily: a case report and review of the literature.他莫昔芬在每日20毫克治疗进展后将剂量增至每日40毫克诱导乳腺癌缓解：一例病例报告及文献综述
Cancer. 1981 Aug 15;48(4):873-5. doi: 10.1002/1097-0142(19810815)48:4<873::aid-cncr2820480402>3.0.co;2-1.
2
Trial of tamoxifen at a dose of 40 mg daily after disease progression during tamoxifen therapy at a dose of 20 mg daily.
Cancer Treat Rep. 1982 Jun;66(6):1445-6.
3
A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.两种剂量他莫昔芬（诺瓦得士）治疗绝经后晚期乳腺癌女性的比较：每日两次，每次10毫克与每日两次，每次20毫克。
Br J Cancer. 1984 Aug;50(2):199-205. doi: 10.1038/bjc.1984.163.
4
Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen.人乳腺癌细胞系对他莫昔芬生长抑制作用的差异敏感性。
Cancer Res. 1985 Apr;45(4):1525-31.
5
The clinical course of bone metastases from breast cancer.乳腺癌骨转移的临床病程。
Br J Cancer. 1987 Jan;55(1):61-6. doi: 10.1038/bjc.1987.13.
6
Triphenylethylenes: a new class of protein kinase C inhibitors.
J Natl Cancer Inst. 1986 Jun;76(6):1243-6.
7
Anti-oestrogen therapy of advanced mammary carcinoma.
Acta Radiol Ther Phys Biol. 1976 Dec;15(6):513-8. doi: 10.3109/02841867609131975.
8
Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland.
Eur J Cancer (1965). 1978 Nov;14(11):1291-2. doi: 10.1016/0014-2964(78)90238-4.
Zotero 插件